Categories: News

Bioz and Resonac America (Shodex) Partner to Enable Researchers to Leverage Citations to Choose Analytical Liquid Chromatography Products

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

PALO ALTO, CA / ACCESSWIRE / September 3, 2024 / Bioz, Inc., an innovative research-focused AI company, is pleased to announce its partnership with Resonac America, a globally recognized company in the field of liquid chromatography (LC). Its ShodexTM brand LC columns have been manufactured by Showa Denko K.K. (Resonac Corporation as of 2023) in Japan since 1973. Shodex is best known for innovative polymer-based columns offering size-exclusion chromatography, HILIC, and sugar analysis columns.

Bioz Prime Badge
Bioz Prime Badges on the Resonac (Shodex) Website

As an established player in the LC industry, Resonac has amassed over 25,000 product mentions in peer-reviewed scientific publications. These citations are displayed on Shodex’s product webpages within dynamic Bioz Badges, and also on Shodex’s citation webpage within a Bioz Content Hub. Bioz Badges and Content Hubs are unique interactive web-based widgets that enable researchers to view the usage context of the product from within the scientific literature, aiding in their purchasing decision-making process.

“Shodex customers are now easily able to evaluate their colleagues’ research using LC columns directly on Resonac’s product webpages,” said Dr. Karin Lachmi, co-founder and CRO at Bioz. “This is a major leap forward for researchers who are in the evaluation stage of choosing products for their analytical applications,” added Dr. Lachmi.

Dr. Ron Benson, Director of Product Development – Americas at Resonac (Shodex), highlighted that “Bioz Badges and the Content Hub allow both new and repeat customers alike to evaluate Shodex product usage by viewing citations from their fellow researchers.” Dr. Benson added, “Bioz tools have been invaluable as a way for us to demonstrate how our products can and should be used in scientific research.”

About Bioz

Bioz is the world’s most advanced AI search engine for life science experimentation, with evidence-based product ratings and recommendations to guide biopharma and academic scientists toward the most-validated products to use in their experiments, which accelerates research toward new discoveries. Bioz solutions for suppliers include Bioz Badges and Content Hubs, web-based widgets, that are placed on product supplier websites to increase user engagement and sales conversion.

Helpful Links

To learn more about Bioz solutions for suppliers, please reach out to info@bioz.com.

Contact Information

Daniel Levitt
CEO
pr@bioz.com

SOURCE: Bioz, Inc.

View the original press release on newswire.com.

Staff

Recent Posts

BioSig Technologies Confirms Full Compliance with Nasdaq Requirements for Continued Listing on The Nasdaq Capital Market

Los Angeles, CA, March 26, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BSGM) (“BioSig” or…

2 hours ago

Dr. Lyudmila Sarder Receives Prestigious U.S. Congressional Award for Women’s History Month

"Trailblazing Physician and Advocate Receives U.S. Congressional Award for Advancing Healthcare Access and Community Service…

2 hours ago

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™…

2 hours ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”,…

2 hours ago

Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider

Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published by…

2 hours ago

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE…

2 hours ago